NeuroSigma is a Los Angeles, California-based bioelectronic medical device company developing technologies to transform medical practice and patients' lives. The company's lead product is the Monarch eTNS System, which is the first non-drug treatment for pediatric ADHD cleared by the FDA. Pipeline indications for the Monarch eTNS System include neurodevelopmental disorders such as autism spectrum disorder (ASD), learning disabilities, and epilepsy.
Leadership & Board
Current Number of Employees9
Current LinkedIn Followers658
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$1M
Total Amount Raised$1M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$1M
Latest Funding Amount$1M
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
NeuroSigma Inc had 9 employees as of October 5, 2026. The number of employees increased by 0 (0.00%) week-over-week.
9Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
NeuroSigma Inc had 658 followers as of October 5, 2026. The number of followers increased by 9 (1.39%) week-over-week.
658Latest Followers Count
9(1.39%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.